Sanofi-Aventis touts survival data in Taxotere study
In a head-to-head study of two of the most popular chemotherapies for breast cancer, Taxotere proved more effective than paclitaxel in prolonging women's lives for certain types of the disease. The study, published in the Journal of Clinical Oncology, focused on women with advanced breast cancer. Women receiving Taxotere survived an average of 15.4 months compared to an overall 12.7 months for patients taking paclitaxel.
- read this report from AFX for more
More stories about Paclitaxel
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
